Swiss NovImmune wins Biotechnica award in Hanover
The Biotechnica, one of the largest and longest-running fairs in the life sciences sector in Europe, opened its gates in Hanover on Tuesday. 650 exhibitors will showcase their products across a display area totalling 11,200 square metres. At the opening night on Monday, the 7th Biotechnica Award was presented to winners NovImmune SA from Switzerland (see more…). NovImmune received a cash prize of EUR30,000 for their development of monoclonal antibodies for the treatment of inflammatory and immune-related disorders. The remaining EUR70,000 has been distributed among all three finalists in the form of non-cash prizes, comprising a consultancy course with Capgemini Consulting focusing on business strategy and investment, plus media packages in European Biotechnology News. The other finalists alongside NovImmune were the biopharmaceutical companies TRION Pharma GmbH from Munich, and VIVALIS SA from Saint Herblain near Nantes, France. "Never before has it been so difficult to reach a decision", commented Peter Stadler, chairman of the eleven-man international prize jury. "All three finalists have impressively demonstrated just how far the biotechnology industry in Europe has come", noted Stadler. NovImmune is based in Plan-les-Ouates near Geneva, Switzerland, and has to date generated seven monoclonal antibodies aimed at treating immune-related disorders. The lead product, NI-0401/anti-CD3, is being currently tested in phase II for Crohn's disease, type 1 diabetes, and transplantation.